Pharvaris reports sustained HAE attack rate reduction

ZUG, Switzerland - Pharvaris (NASDAQ:PHVS), a biopharmaceutical company valued at $862 million, has reported positive long-term data for its oral drug deucrictibant, designed to treat hereditary angioedema (HAE). The company maintains a strong financial position with more cash than debt and a healthy current ratio of 19.08. The findings were presented at the recent AAAAI/WAO Joint Congress and show sustained effectiveness in reducing HAE attacks and improving patients’ quality of life.

The CHAPTER-1 Open-Label Extension (OLE) study, which evaluated deucrictibant as a prophylactic treatment, showed that after an average treatment duration of 12.8 months, participants experienced a median of zero days with HAE symptoms each month. Moreover, health-related quality of life (HRQoL) improved significantly, with notable enhancements in functioning and fear/shame domains. For detailed financial analysis and more insights, InvestingPro subscribers can access comprehensive company metrics and expert research.

In the RAPIDe-2 extension study, focusing on on-demand treatment, deucrictibant’s efficacy was maintained with a median time to symptom relief of 0.9 hours for upper airway attacks. The majority of these attacks were resolved with a single dose, consistent with the treatment of non-upper airway attacks.

Deucrictibant was generally well-tolerated across both studies, with no safety concerns observed. These results support the potential of deucrictibant as an oral therapy for both the prevention and treatment of HAE attacks, offering a significant improvement over current treatment options.

Pharvaris is advancing deucrictibant through pivotal Phase 3 studies to confirm its safety and efficacy profile. Trading near its 52-week low of $14.98, the stock has attracted analyst attention with price targets ranging from $13.82 to $55.05. The company aims to address unmet needs in the HAE community by offering an alternative to injectable treatments with the convenience of an oral medication. InvestingPro reveals 8 additional key insights about Pharvaris’s market position and financial outlook.

This article is based on a press release statement from Pharvaris.

In other recent news, Pharvaris B.V. has been the focus of several analyst updates and clinical trial developments. Analysts at Citizens JMP and JMP Securities have maintained a Market Outperform rating with a $55 price target for Pharvaris, reflecting optimism about its leading drug candidate, deucrictibant. This drug is being evaluated for both on-demand and prophylactic treatment of Hereditary Angioedema (HAE), with promising data from Phase 2 trials and ongoing Phase 3 studies. The RAPIDe-1 trial showed a rapid median onset of symptom relief in 1.1 hours, with complete resolution of attacks in a median time of 11.5 hours, reinforcing confidence in its efficacy.

Furthermore, Pharvaris’s extended-release version of deucrictibant is in a Phase 3 study, with results anticipated in 2026. Analysts have pointed out the company’s unique position with an oral candidate for HAE treatment, potentially offering a more favorable option compared to injectable alternatives. New data also highlighted deucrictibant’s effectiveness in treating upper airway attacks, which could expand its use as an oral treatment option. The analyst firm JMP Securities raised its price target from $46 to $55, citing a revised revenue forecast and a larger addressable patient population. These developments suggest a positive outlook for Pharvaris’s clinical strategy and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.